Navigation Links
Bionovo Announces Enrollment Started in the Menerba (MF101) Phase 1 "Tolerability" Clinical Trial for Menopausal Hot Flushes
Date:3/28/2011

search, Lincoln, CA


  • Telephone: 916-434-8230

  • 2.
    Northern California Research, Sacramento, CA


  • Telephone: 916-484-0500

  • IRB approval has been sought and is expected soon at a third site:3.
    Alta Bates, Jordan Research and Education Institute, Berkeley, CA


  • Telephone: 510-849-0417 extension 12
  • About MenerbaMenerba is an oral drug candidate designed for the safe, effective treatment of vasomotor symptoms (hot flashes) associated with menopause, which is manufactured from botanical sources. Menerba is an estrogen receptor beta (ER-b) selective drug, developed as an alternative to the products currently on the market which have been shown to increase the risk for breast and uterine cancers. It has been shown that the increased risk of breast and uterine cancers is associated with activation of estrogen receptor alpha (ER-a) and that activation of estrogen receptor beta (ER-b) blocks the growth promoting effects on breast cancer cells. The active ingredients in Menerba are derived from botanicals with centuries of recorded safe, effective use in traditional Chinese medicine (TCM). Bionovo recognizes the opportunity to commercialize a product that would be as effective as hormone therapy, without the health risks. Menerba has completed a Phase 2 trial with positive results for efficacy and has been evaluated by an independent Data and Safety Monitoring Board and passed through a standard two-round examination for safety. Menerba also has been shown in animal studies to prevent the proliferation of breast cancer and to have a beneficial effect on osteoporosis, though this has not yet been studied in humans.

    About Bionovo, Inc.Bionovo, Inc. is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual reven
    '/>"/>

    SOURCE Bionovo, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Bionovo Announces 2010 Highlights and Year-End Financial Results
    2. Bionovo, Inc. to Announce Fourth Quarter Fiscal Year 2010 Financial Results on Tuesday, March 15, 2011
    3. Bionovo to Present at the Cowen and Company 31st Annual Healthcare Conference
    4. Bionovo Announces 2011 Plan of Action on MF101 (Menerba™)
    5. Bionovo Announces Pricing of Follow-on Offering of Common Stock and Warrants
    6. Bionovo Announces Publication Describing How Metabolic Adaptability Contributes to the Metastasis of Tumors
    7. Bionovo Releases FDA-Approved Clinical Development Plan for Menerba
    8. Bionovo Announces Publication Describing Estrogen Receptor Beta Cancer Prevention Mechanism
    9. Bionovo Announces Third Quarter 2010 Highlights and Financial Results
    10. Bionovo, Inc. to Announce Third Quarter Fiscal Year 2010 Financial Results on Thursday, November 11, 2010
    11. Bionovo Announces Publication Describing Potential Estrogen Receptor Modulating Drugs for Treating Menopausal Conditions
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2014)... 31, 2014  Cepheid (NASDAQ: CPHD ) today ... conferences, and invited investors to participate via webcast. ... New York, NY Wednesday, August 13, 2014 at ... Conference, New York, NY Thursday, September ... Accessing Live Webcasts To access the live webcasts for these ...
    (Date:7/31/2014)... Fla. , July 31, 2014 Rock ... today that it has initiated the development of its ... ; and that it has selected Quotient Clinical, The ... Kingdom (UK) to run its early development ... Clinical Trial Application (CTA) by the end of the ...
    (Date:7/31/2014)... , July 31, 2014 Lazarus Effect, ... novel interventional devices to facilitate removal of blood clots, ... from the financing will support EU commercialization of several ... for the Lazarus ReCover™ and Lazarus Cover™ in ... financing reflects investor confidence in the value of our ...
    Breaking Medicine Technology:Cepheid to Webcast Upcoming Financial Presentations 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4Lazarus Effect Closes $5 Million Financing 2
    (Date:7/31/2014)... 2014) If you have asthma, you may have an ... you recognize and respond to changes and understand when symptoms ... the green zone, you,re doing well, yellow means your asthma ... require urgent care. New guidelines are now available to help ... into green and away from the red zone. , "Management ...
    (Date:7/31/2014)... GA (PRWEB) July 31, 2014 Developer ... camera on its Ponce City Market project in ... historic Sears, Roebuck & Company building into best-in-class office, ... completion, OxBlue reviewed Jamestown’s experience with their construction webcam ... , Jamestown wanted a construction camera ...
    (Date:7/31/2014)... 31, 2014 Hoping to attract new customers ... trust , NutriGold is ready to ship out free ... make taking advantage of this offer fast and easy: ... and Development at NutriGold, "We know that every time customers ... their most precious asset: their own health or the health ...
    (Date:7/31/2014)... Ce-Classes.com has announced that they are now offering a ... Systematic Review of Sexual Satisfaction . The course ... of Clinical and Health Psychology. , This CE course ... have accurate information about sexual satisfaction so that healthcare ... material provides a systematic review of 197 research publications ...
    (Date:7/31/2014)... Dr. Stewart Shofner of Shofner Vision ... in the United States to successfully treat glaucoma by performing ... device ever approved by the FDA. Dr. Shofner is ... of using a procedure known as Selective Laser Trabeculoplasty (SLT) ... colleagues now recognize that this procedure is a primary treatment ...
    Breaking Medicine News(10 mins):Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 3Health News:NutriGold Launches Product Samples Page for its Supplements 2Health News:NutriGold Launches Product Samples Page for its Supplements 3Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 2Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 3Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 4
    ... Inc. (OTC Bulletin Board: CARN) today said the ... be webcast live from the Kennedy I Room ... Healthcare Conference at New York City,s Palace Hotel ... The presentation will cover DelSite,s three key ...
    ... CAMBRIDGE, Mass., Nov. 5 Abt Associates has ... Office of Planning, Research,and Evaluation within the U.S. ... and Families (ACF) to lead a major evaluation,of ... and former recipients of Temporary Assistance for Needy ...
    ... Care Awareness Week, WASHINGTON, Nov. 5 ... coverage for long-term care expenses,according to new survey ... The survey found that many Baby Boomers have ... have not thought about,long-term care insurance. (Logo: ...
    ... Relaxation in large, sound- and light-proof tanks with ... stress-related pain. This has been shown by Sven-ke ... with a dissertation from Karlstad University in Sweden. ... have indicated: sleep was improved, patients felt more ...
    ... may be more accurate than existing biological signposts ... into advanced forms of the disease. , ... edition of the International Journal of Cancer, the ... prevent patients from unnecessarily undergoing aggressive cancer treatments. ...
    ... /Xinhua-PRNewswire-FirstCall/ -- China Holdings, Inc.,(OTC Bulletin Board: ... its subsidiaries engage in multiple China-focused business ... real,estate, and pharmaceuticals, announced today the Company ... exclusive rights to develop and construct,the 2nd ...
    Cached Medicine News:Health News:Carrington's DelSite Presentation at Rodman & Renshaw Conference to be Webcast Live on November 7th 2Health News:Abt Associates to Lead Major Evaluation of Programs Aimed at Promoting Self-Sufficiency for Disadvantaged Families 2Health News:New Survey Finds One in Four Baby Boomers Erroneously Believe They Have Coverage for Long-Term Care Expenses 2Health News:New Survey Finds One in Four Baby Boomers Erroneously Believe They Have Coverage for Long-Term Care Expenses 3Health News:Floating effective for stress and pain 2Health News:Biomarker may be an early predictor of advanced breast cancer 2Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 2Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 3Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 4Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 5Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 6Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 7Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 8
    CUSA DISSECTRON PORTABLE UNIT is an ultrasonic surgical aspirator for the fragmentation and emulsification of tissue available only outside the United States....
    The Nevyas Drape Support is the simple and inexpensive way to establish a zone of comfort for your patients during ophthalmic surgery which requires draping over the nose and mouth. Packaged in sets ...
    This is a 2.5x focusing Galilean telescope with a range from 70cm to infinity. Ideal for use at sporting events, as well as for a wide range of hobbies....
    ... us to the practical limit of ... often a 'last resort' option for ... The illuminated housing ensures a constant ... battery handle by a lightweight cord ...
    Medicine Products: